

Skin Cancer Melanoma

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04091217 ML41186

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04091217 ML41186
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No
